ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.
ESSA Pharma Inc (EPIX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.039x
Based on the latest financial reports, ESSA Pharma Inc (EPIX) has a cash flow conversion efficiency ratio of -0.039x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.20 Million) by net assets ($108.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ESSA Pharma Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how ESSA Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ESSA Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ESSA Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hapbee Technologies Inc
PINK:HAPBF
|
0.979x |
|
PT UBC Medical Indonesia Tbk
JK:LABS
|
0.063x |
|
PT Jobubu Jarum Minahasa Tbk
JK:BEER
|
-0.001x |
|
Magna Prima Bhd
KLSE:7617
|
0.155x |
|
PT Hasnur Internasional
JK:HAIS
|
0.073x |
|
Barksdale Resources Corp
OTCQX:BRKCF
|
-0.058x |
|
Wishpond Technologies Ltd
OTCQX:WPNDF
|
-0.016x |
|
BKG Viet Nam Investment JSC
VN:BKG
|
N/A |
Annual Cash Flow Conversion Efficiency for ESSA Pharma Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of ESSA Pharma Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $124.61 Million | $-22.72 Million | -0.182x | -34.21% |
| 2023-09-30 | $145.63 Million | $-19.78 Million | -0.136x | +20.91% |
| 2022-09-30 | $167.12 Million | $-28.70 Million | -0.172x | -31.11% |
| 2021-09-30 | $194.01 Million | $-25.42 Million | -0.131x | +38.87% |
| 2020-09-30 | $79.24 Million | $-16.98 Million | -0.214x | +13.96% |
| 2019-09-30 | $49.18 Million | $-12.25 Million | -0.249x | +77.69% |
| 2018-09-30 | $9.15 Million | $-10.22 Million | -1.116x | -127.50% |
| 2017-09-30 | $-4.27 Million | $-17.35 Million | 4.061x | -85.75% |
| 2016-09-30 | $-537.00K | $-15.30 Million | 28.493x | +1125.81% |
| 2015-09-30 | $4.43 Million | $-12.30 Million | -2.778x | -163.48% |
| 2014-09-30 | $1.97 Million | $-2.08 Million | -1.054x | -66058.28% |
| 2013-09-30 | $479.04K | $-763.35 | -0.002x | +99.89% |
| 2012-09-30 | $1.31K | $-1.82K | -1.396x | -- |